|Videos|February 4, 2015

Mitch DeKoven Says AJMC Is Top of Mind in Managed Care

Among publications in the managed care field, The American Journal of Managed Care (AJMC) is likely the leader, according to Mitch DeKoven, principal of health economics and outcomes research at IMS Health.

Among publications in the managed care field, The American Journal of Managed Care (AJMC) is likely the leader, according to Mitch DeKoven, principal of health economics and outcomes research at IMS Health.

He added that for IMS Health, which does work for the payer world, AJMC “comes to mind immediately.”

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Dr Julie Kanter | Image Credit: Inherited Blood Disorders

Mitch DeKoven Says AJMC Is Top of Mind in Managed Care

Related Content

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

Managing Toxicity, Sequencing for Long-Term BTKIs: Kerry Rogers, MD

Early SENTRY Data Suggest Benefit of Selinexor-Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis: Claire Harrison, MD

Class III Obesity May Benefit Most From AI-CGM Engagement: Stephanie Kim, MD, MPH

Coding, Coverage Gaps Hamper Multidisciplinary Obesity Care

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Mitch DeKoven Says AJMC Is Top of Mind in Managed Care

Related Content

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

Managing Toxicity, Sequencing for Long-Term BTKIs: Kerry Rogers, MD

Early SENTRY Data Suggest Benefit of Selinexor-Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis: Claire Harrison, MD

Class III Obesity May Benefit Most From AI-CGM Engagement: Stephanie Kim, MD, MPH

Coding, Coverage Gaps Hamper Multidisciplinary Obesity Care

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF